270 related articles for article (PubMed ID: 33414227)
1. Regional and Volumetric Parameters for Diffusion-Weighted WHO Grade II and III Glioma Genotyping: A Method Comparison.
Thust SC; Maynard JA; Benenati M; Wastling SJ; Mancini L; Jaunmuktane Z; Brandner S; Jäger HR
AJNR Am J Neuroradiol; 2021 Mar; 42(3):441-447. PubMed ID: 33414227
[TBL] [Abstract][Full Text] [Related]
2. World Health Organization Grade II/III Glioma Molecular Status: Prediction by MRI Morphologic Features and Apparent Diffusion Coefficient.
Maynard J; Okuchi S; Wastling S; Busaidi AA; Almossawi O; Mbatha W; Brandner S; Jaunmuktane Z; Koc AM; Mancini L; Jäger R; Thust S
Radiology; 2020 Jul; 296(1):111-121. PubMed ID: 32315266
[TBL] [Abstract][Full Text] [Related]
3. Apparent diffusion coefficient for molecular subtyping of non-gadolinium-enhancing WHO grade II/III glioma: volumetric segmentation versus two-dimensional region of interest analysis.
Thust SC; Hassanein S; Bisdas S; Rees JH; Hyare H; Maynard JA; Brandner S; Tur C; Jäger HR; Yousry TA; Mancini L
Eur Radiol; 2018 Sep; 28(9):3779-3788. PubMed ID: 29572636
[TBL] [Abstract][Full Text] [Related]
4. Predicting Genotype and Survival in Glioma Using Standard Clinical MR Imaging Apparent Diffusion Coefficient Images: A Pilot Study from The Cancer Genome Atlas.
Wu CC; Jain R; Radmanesh A; Poisson LM; Guo WY; Zagzag D; Snuderl M; Placantonakis DG; Golfinos J; Chi AS
AJNR Am J Neuroradiol; 2018 Oct; 39(10):1814-1820. PubMed ID: 30190259
[TBL] [Abstract][Full Text] [Related]
5. Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas.
Leu K; Ott GA; Lai A; Nghiemphu PL; Pope WB; Yong WH; Liau LM; Cloughesy TF; Ellingson BM
J Neurooncol; 2017 Aug; 134(1):177-188. PubMed ID: 28547590
[TBL] [Abstract][Full Text] [Related]
6. Diffusion- and perfusion-weighted MRI radiomics model may predict isocitrate dehydrogenase (IDH) mutation and tumor aggressiveness in diffuse lower grade glioma.
Kim M; Jung SY; Park JE; Jo Y; Park SY; Nam SJ; Kim JH; Kim HS
Eur Radiol; 2020 Apr; 30(4):2142-2151. PubMed ID: 31828414
[TBL] [Abstract][Full Text] [Related]
7. Advanced imaging parameters improve the prediction of diffuse lower-grade gliomas subtype, IDH mutant with no 1p19q codeletion: added value to the T2/FLAIR mismatch sign.
Lee MK; Park JE; Jo Y; Park SY; Kim SJ; Kim HS
Eur Radiol; 2020 Feb; 30(2):844-854. PubMed ID: 31446467
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic performance of gliomas grading and IDH status decoding A comparison between 3D amide proton transfer APT and four diffusion-weighted MRI models.
Guo H; Liu J; Hu J; Zhang H; Zhao W; Gao M; Zhang Y; Yang G; Cui Y
J Magn Reson Imaging; 2022 Dec; 56(6):1834-1844. PubMed ID: 35488516
[TBL] [Abstract][Full Text] [Related]
9. Apparent Diffusion Coefficient as Imaging Biomarker for Identifying IDH Mutation, 1p19q Codeletion, and MGMT Promoter Methylation Status in Patients With Glioma.
Ma X; Cheng K; Cheng G; Li C; Lyu J; Lan Y; Duan C; Bian X; Zhang J; Lou X
J Magn Reson Imaging; 2023 Sep; 58(3):732-738. PubMed ID: 36594577
[TBL] [Abstract][Full Text] [Related]
10. Molecular Subtype Classification in Lower-Grade Glioma with Accelerated DTI.
Aliotta E; Nourzadeh H; Batchala PP; Schiff D; Lopes MB; Druzgal JT; Mukherjee S; Patel SH
AJNR Am J Neuroradiol; 2019 Sep; 40(9):1458-1463. PubMed ID: 31413006
[TBL] [Abstract][Full Text] [Related]
11. A Comparative Study of 2 Different Segmentation Methods of ADC Histogram for Differentiation Genetic Subtypes in Lower-Grade Diffuse Gliomas.
Liu D; Gao SX; Liao HF; Xu JM; Wen M
Biomed Res Int; 2020; 2020():9549361. PubMed ID: 33062706
[TBL] [Abstract][Full Text] [Related]
12. MRI Features and IDH Mutational Status of Grade II Diffuse Gliomas: Impact on Diagnosis and Prognosis.
Villanueva-Meyer JE; Wood MD; Choi BS; Mabray MC; Butowski NA; Tihan T; Cha S
AJR Am J Roentgenol; 2018 Mar; 210(3):621-628. PubMed ID: 29261348
[TBL] [Abstract][Full Text] [Related]
13. Whole-Tumor Histogram and Texture Analyses of DTI for Evaluation of
Park YW; Han K; Ahn SS; Choi YS; Chang JH; Kim SH; Kang SG; Kim EH; Lee SK
AJNR Am J Neuroradiol; 2018 Apr; 39(4):693-698. PubMed ID: 29519794
[TBL] [Abstract][Full Text] [Related]
14. Feasibility of evaluating the histologic and genetic subtypes of WHO grade II-IV gliomas by diffusion-weighted imaging.
Liu S; Zhang Y; Kong Z; Jiang C; Wang Y; Zhao D; You H; Ma W; Feng F
BMC Neurosci; 2022 Dec; 23(1):72. PubMed ID: 36471242
[TBL] [Abstract][Full Text] [Related]
15. Whole-Tumor Histogram Analysis of Multiple Diffusion Metrics for Glioma Genotyping.
Gao A; Zhang H; Yan X; Wang S; Chen Q; Gao E; Qi J; Bai J; Zhang Y; Cheng J
Radiology; 2022 Mar; 302(3):652-661. PubMed ID: 34874198
[TBL] [Abstract][Full Text] [Related]
16. Diffusion and perfusion MRI may predict EGFR amplification and the TERT promoter mutation status of IDH-wildtype lower-grade gliomas.
Park YW; Ahn SS; Park CJ; Han K; Kim EH; Kang SG; Chang JH; Kim SH; Lee SK
Eur Radiol; 2020 Dec; 30(12):6475-6484. PubMed ID: 32785770
[TBL] [Abstract][Full Text] [Related]
17. Prediction of Isocitrate Dehydrogenase Genotype in Brain Gliomas with MRI: Single-Shell versus Multishell Diffusion Models.
Figini M; Riva M; Graham M; Castelli GM; Fernandes B; Grimaldi M; Baselli G; Pessina F; Bello L; Zhang H; Bizzi A
Radiology; 2018 Dec; 289(3):788-796. PubMed ID: 30277427
[TBL] [Abstract][Full Text] [Related]
18. Magnetic resonance imaging criteria for prediction of isocitrate dehydrogenase (IDH) mutation status in patients with grade II-III astrocytoma and oligodendroglioma.
Çelik S; Öven BB; Demir MK; Yılmaz EÇ; Kanan D; Özdamarlar U; Emirzeoglu L; Yapıcıer Ö; Kılıç T
Clin Neurol Neurosurg; 2021 Aug; 207():106745. PubMed ID: 34146841
[TBL] [Abstract][Full Text] [Related]
19. A three-component multi-b-value diffusion-weighted imaging might be a useful biomarker for detecting microstructural features in gliomas with differences in malignancy and IDH-1 mutation status.
Cao M; Wang X; Liu F; Xue K; Dai Y; Zhou Y
Eur Radiol; 2023 Apr; 33(4):2871-2880. PubMed ID: 36346441
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of isocitrate dehydrogenase mutation in 2021 world health organization classification grade 3 and 4 glioma adult-type diffuse gliomas with 18F-fluoromisonidazole PET.
Wang Y; Fushimi Y; Arakawa Y; Shimizu Y; Sano K; Sakata A; Nakajima S; Okuchi S; Hinoda T; Oshima S; Otani S; Ishimori T; Tanji M; Mineharu Y; Yoshida K; Nakamoto Y
Jpn J Radiol; 2023 Nov; 41(11):1255-1264. PubMed ID: 37219717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
